[Newsmp] Korea’s Ministry of Food and Drug Safety said on Wednesday it has approved Sanofi-Aventis Korea’s acid sphingomyelinase deficiency (ASMD) therapy Xenpozyme (ingredient: olipudase alfa).
ASMD arises from a deficiency in an essential enzyme responsible for breaking down a complex lipid known as sphingomyelin, leading to its accumulation in the liver, spleen, lungs, and brain.
Xenpozyme is a recombinant human ASM that reduces sphingomyelin (SM) accumulation in the patient’s organs.
"We will continue to do our best to promptly supply treatments with sufficient safety and effectiveness based on regulatory science," the ministry said in a release.
저작권자 © 의약뉴스 무단전재 및 재배포 금지
